Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00431873 | A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia | PHASE2 | COMPLETED | 21 | — | — | Jan 1, 2007 | Nov 1, 2008 | Jul 1, 2015 | 13 | United States, Canada |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | MGCD0103 administered orally three times per week. |
| Name | Type | Description |
|---|---|---|
| MGCD0103 | DRUG | MGCD0103 Administered orally three times per week. |
Inclusion Criteria: * Pathologic confirmation of CLL. * Prior Treatment. There will be no limit to prior therapy. Therapy with fludarabine and Rituxan must have failed (disease progression, intolerance, or not a candidate). * Age 18 years or greater. * ECOG performance status of 0 or 1. * Laborator...